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Abstract
Background: Carpal tunnel syndrome (CTS) is the most common form of peripheral nerve injury, affecting
approximately 3 % of the population. While surgery is effective in mild and moderate cases, nerve and functional
recovery are often not complete in severe cases. Therefore, there is a need for adjuvant methods to improve
nerve regeneration in those cases. Acetyl-L-carnitine (ALCAR) is involved in lipid transport, vital for mitochondrial
function. Although it has been shown to be effective in various forms of neuropathies, it has not been used in
traumatic or compressive peripheral nerve injury.
Methods: In this pilot study we will utilize a double-blind, randomized, placebo-controlled design. Inclusion
criteria will include adult patients with severe CTS. This will be confirmed by nerve conduction studies and motor
unit number estimation (MUNE). Only those with severe motor unit loss in the thenar muscles (2 standard
deviations [SD] below the mean for the age group) will be included. Eligible patients will be randomized to
receive 3,000 mg/day of ALCAR orally or placebo following carpal tunnel release surgery for 2 months. The primary
outcome will be MUNE with supplementary secondary outcome measures that include: 1) two-point discrimination; 2)
Semmes-Weinstein monofilaments for pressure sensitivity; 3) cold and pain threshold for small fiber function; 4) Boston
self-assessment Carpal Tunnel Questionnaire and 5) Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire for
symptom severity; and 6) Purdue Pegboard Test for hand functional performance. To follow post treatment recovery
and monitor safety, patients will be seen at 3 months, 6 months and 1 year. The outcome measures will be
analyzed using two-way ANOVA, with treatment assignment and time points being the independent factors. If
significant associations are detected, a post hoc analysis will be completed. We aim to recruit ten patients into
each of the two groups. Data from this pilot will provide the basis for power calculation for a full-scale trial.
Discussion: ALCAR is a physiologic peptide crucial for fatty acid transport. ALCAR has been shown to be effective
in neuroprotection in the central nervous system and increase peripheral nerve regeneration. This has been
applied clinically to various systemic peripheral neuropathies including diabetic neuropathy, antiretroviral toxic
neuropathy, and chemotherapy-induced peripheral neuropathy. While animal evidence exists for the benefit of
ALCAR in compression neuropathy, there have been no human studies to date. This trial will represent the first
use of ALCAR in peripheral nerve injury/compression neuropathy.
Trial registration: NCT02141035; 20 April 2015
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Background
Carpal tunnel syndrome (CTS) is the most common per-
ipheral nerve injury. Based on the clinical assessment of
3,000 randomly chosen individuals in Sweden, the preva-
lence of confirmed CTS was almost 3 % in the general
population [1]. Of those, 25 % had severe symptoms and
nerve injury that could not be sufficiently managed through
conservative means [2]. The large number of afflicted indi-
viduals poses a major healthcare cost and social economic
burden [3]. Indeed, it is estimated that up to half a million
patients undergo surgery for CTS each year in the United
States with an associated healthcare cost that exceeds $2
billion [4]. Therefore, much effort has been spent on
attempts to improve treatment outcomes. Although conser-
vative measures such as wrist splinting can be effective in
milder cases, surgery is needed to relieve pressure on the
median nerve when conservative measures fail. However,
even with surgery, the outcome in more severe cases in
which substantial axonal degeneration has already occurred
remains poor [5]. One major reason is that even though
injured nerve fibers have an inherent ability to regenerate,
the regeneration proceeds very slowly with rates of only
1 mm/day in ideal circumstances [6, 7]. The regenerative
capacity of axons and the Schwann cell (SC) growth sup-
port decline with time and distance from injury [8, 9].
To improve the speed and extent of nerve regeneration,
novel treatment strategies are being explored. While de-
compression surgery is useful in alleviating further mech-
anical injury to the median nerve, it does little to influence
the underlying molecular mechanisms of peripheral nerve
regeneration. Although a number of potential therapeutic
agents including FK506 [10], geldanamycin [11] and fibro-
blast growth factor [12] have been studied, their safety and
tolerability for human application have challenges. In con-
trast, acetyl-L-carnitine (ALCAR) has an excellent safety
track record for human use. It is a naturally occurring
molecule that acts as an acetyl donor group that is crit-
ical for lipid transport and the maintaining of mito-
chondrial function. In vitro studies showed that
ALCAR promoted cerebellar neuronal maturation and
increased peripheral nerve regeneration in animal
studies [13]. These findings prompted the evaluation
of ALCAR in various neuropathies to improve nerve
regeneration. Clinical conditions studied include anti-
retroviral toxic neuropathy [14], diabetic neuropathy [15]
and chemotherapy-induced neuropathy [16]. Those stud-
ies showed that patients treated with ALCAR have less
pain and better motor and sensory function. While this
data is encouraging, the use of ALCAR in patients with
compressive neuropathies remains largely untested. In an
animal study, Kotil et al. found histopathological evidence
of improvement when ALCAR was administered on its
own or with concomitant decompression surgery [17].
The only human study to date that includes compression
neuropathies was primarily designed to examine the toler-
ability of ALCAR [18]. However, evidence of nerve regen-
eration was not a primary objective of that study.
Objective
The objective of the trial is to determine the efficacy of
ALCAR on nerve regeneration in patients with severe CTS.
Hypothesis
ALCAR will significantly increase motor axonal regener-




This double-blinded, placebo-controlled trial has re-
ceived ethics approval from the University of Alberta
Health Ethics Research Board (Pro00045538). The study
protocol has been reviewed by Health Canada, and a No
Objection Letter (NOL) has been issued for the use of
ALCAR. Subjects will be recruited from plastic surgery
clinics at the University of Alberta Hospital and Royal
Alexandra Hospital as well as the electromyography
(EMG) clinic at the Glenrose Rehabilitation Hospital.
Subjects
All patients referred to either the plastic surgery clinics
or the EMG lab will be eligible to be screened. Inclusion
into the study will be based upon the criteria listed in
Table 1. Patients meeting eligibility criteria will be re-
cruited and informed consent will be obtained. They will
then undergo motor unit number estimation (MUNE) to
quantify the severity of motor axonal loss. Only those
with motor axonal loss of > 2 SD below the mean for the
age group will be included in the study.
Randomization
After enrollment, patients will be randomized to placebo
or ALCAR. A randomization sequence will be generated
electronically and kept by a statistician not directly in-
volved in patient care. Randomization will be kept on a
computer under password encryption. The randomization
code will only be broken if a patient experiences a severe
adverse event. At the end of the study the statistician will
provide the research team with the randomization codes.
Blinding
The study will be administered in a double-blind man-
ner. The randomization sequence will be kept confiden-
tial and only accessible to authorized personnel. The
pharmacy will distribute identical pills in bottles labeled
with A or B. The research team will be unaware of
which contains the study drug or placebo. This will be
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maintained until the final follow-up has occurred, at
which point the research team will be unblinded.
Primary outcome
The primary endpoint will be motor axon reinnervation
in the thenar muscles. This will be done using MUNE, a
non-invasive electrophysiological technique. Initially in-
troduced in the 1970s [19, 20], multipoint stimulation,
the most commonly used MUNE technique, has been
shown to be a reliable test for measuring motor axon re-
innervation [5]. Apart from providing an objective as-
sessment of large myelinated nerve fibers, MUNE will
also serve as a screening tool for eligibility for the trial.
To quantify treatment response, MUNE will be repeated
at 3, 6 and 12 months post-operatively.
Secondary outcomes
Secondary outcomes of the study focus on sensory function
restoration and functional outcomes. Measures will include:
1. Two-point discrimination (Aβ fibers) using
Dellon-MacKinnon Disk
2. Pressure sensitivity (Aβ fibers) using Semmes-
Weinstein monofilament
3. Cold threshold (Aδ fibers) and pain threshold
(C fibers) using CASE IV quantitative sensory
testing (QST) equipment
4. Boston CTS Questionnaire to monitor symptom
severity
5. Disabilities of the Arm, Shoulder and Hand (DASH)
questionnaire for functional outcomes
6. Moberg Pick-up Test to measure hand dexterity and
functional performance
All outcome measures will be monitored at baseline,
3 months, 6 months and 12 months. Sensory testing of
peripheral nerves provides more of a challenge, given
the multiple fiber types that provide sensory feedback.
The above list of tests is designed to capture the full
range of sensory fiber functions. A major advantage of
QST is that it provides an objective means of measuring
the function of different classes of nerve fibers with good
reliability. The DASH and the Boston questionnaires
used to evaluate symptom severity are both well vali-
dated in CTS [21]. Finally, to objectively measure hand
functional performance, the Moberg Pick-up Test is a
validated tool for CTS with good reliability [22]. All pri-
mary and secondary outcome measures will be per-
formed by the same investigators (MC, KMC). To verify
the inter-rater reliability of these tests, a subset of pa-
tients will undergo separate assessment by two investiga-
tors independently in a blinded manner.
Interventions
Patients will be assigned to either the placebo or
ALCAR arm of the study. Both placebo and ALCAR
will be fabricated by the same pharmaceutical company
(Sigma-Tau, Rome, Italy). They are identical in appear-
ance and taste. Upon arrival, the tablets will be pack-
aged by the pharmacy into identical boxes labeled with
a random sequence code. Both groups will undergo open
carpal tunnel release without epineurolysis performed by
experienced hand surgeons (JO, MM). Post-operatively,
patients will take the medications for 2 months. Patients
randomized to the ALCAR arm will take 3,000 mg orally
divided in three times per day dosing, while the control
group will take a matched placebo. The dosing schedule
for the study drug was chosen based on previous work by
Bianchi et al. (2005) that showed good tolerability
and efficacy [23].
Sample size
Initially, a pilot study of 20 patients will be carried out.
Evaluation of the effect size will be based on the primary
outcome MUNE. This will provide the necessary data
for the sample size calculation for a fully powered large-
scale study.
Statistical analysis
Demographic data will be compiled and analyzed for dif-
ferences using a Student’s t-test and Fisher’s exact test.
Table 1 Inclusion and exclusion criteria for patient selection
Inclusion criteria Exclusion criteria
1) Age > 18 years 1) Motor unit loss in the median
nerve less than 2 standard
deviations below the mean
for the age group
2) One or more of the following
symptoms of CTS
2) Presence of other neurologic
conditions
a) Numbness and paresthesias in
the median nerve distributions
3) Previous carpal tunnel release
b) Precipitation of those symptoms
by repetitive motions that are
relieved by rubbing and/or
shaking
4) Cognitive impairment that
renders the patient incapable
of providing consent
c) Nocturnal awakening of the
above symptoms
5) History of seizures




7) Sensitivity to any of the
drug components of the
formulation or are
8) Pregnant/breast feeding
9) For women of child-bearing
potential, those that are not
willing to use adequate
contraceptive prevention
methods for at least 30 days
after the last dose of the
medication.
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The primary and secondary outcome measures will be an-
alyzed using two-way ANOVA with the treatment groups
and time points being the independent factors. If signifi-
cant associations are detected, a post hoc analysis will be
done for pairwise comparisons. Due to the exploratory na-
ture of the study, sample size calculations and formal ana-
lysis of missing data will not be undertaken.
Safety and potential risks
To monitor any potential adverse events, rigorous safety
measures have been put in place to ensure patient safety.




4. Urine pregnancy tests
5. Complete blood count with differential, electrolytes
(Na, K, Cl, CO2), creatinine, urea, alanine
aminotransferase, aspartate aminotransferase,
alkaline phosphatase and bilirubin
6. Serum ALCAR
Vital signs (blood pressure, temperature, pulse, respira-
tory rate, oxygen saturation) will be recorded at every visit.
Safety lab tests including blood chemistries will be done at
screening, and periodically during follow-up visits. In
addition, an electrocardiogram will be done at screening.
The serum ALCAR level will also be monitored. In
healthy subjects, the serum ALCAR levels had a range of
10–70 μmol/L with a mean of 39 μmol/L. In a large study
of over 333 patients with diabetic neuropathy taking 3 g of
ALCAR/day (the same dose used in this study), the rise in
serum level was only around 50 % compared to baseline.
Since no sign of ALCAR toxicity was observed in any of
the subjects, we anticipate that the chances of toxic effects
in this study will be very small.
All adverse events will be documented at follow-up
visits. Further laboratory investigations will be done de-
pending on the nature and severity of the adverse events
reported.
Trial management
The trial will be managed by a trial steering committee in
accordance with Good Clinical Practice guidelines. The
principle investigator, K. Ming Chan (KMC), will be pri-
marily responsible for the overall trial functioning with as-
sistance from Matthew Curran (MC). The administration
of the study drug will be completed through the Research
Pharmacy Office located at the Kaye Edmonton Clinic.
Adverse events will be tracked and managed by a Drug
Safety Monitoring Board. The trial has been registered
with Clinicaltrials.gov (CT02141035).
Research team
Our group, as part of the Western Canada Regeneration
Initiative, has a substantial track record in developing
novel treatments for patients with peripheral nerve injury.
KMC is an experienced clinician scientist in physical
medicine and rehabilitation who will be responsible for
evaluating the treatment outcomes and for overseeing the
project. MC, a resident in the plastic surgery department,
will be responsible for recruitment of patients, evaluating
treatment outcomes and safety, data analysis and manu-
script preparation. Jaret Olson (JO) and Michael Morhart
(MM) are plastic surgeons who will be responsible for
patient recruitment and performing the carpal tunnel re-
lease surgery. All investigators were involved in the study
design and will continue to have a role in result analysis
and writing of the manuscript.
Ethics
The study has ethical approval from the Health Research
Ethics Board (Pro00045538) at the University of Alberta.
The trial will be conducted in keeping with the princi-
ples of Good Clinical Practice.
Discussion
Acetyl-L-carnitine is a peptide natural product that
plays a crucial role in fatty acid metabolism, acyl group
transfer and transport into mitochondria. It has been
shown to be beneficial in a number of disease states in-
cluding oligospermia [24], hepatic encephalopathy [25]
and dysthymia [26]. It has also been shown to have a
positive impact on central and peripheral nervous system
diseases. It can reverse signs of aging in rat brains [27]. In
peripheral neuropathies it is thought that ALCAR en-
hances nerve growth factor receptor binding, allowing for
neurite outgrowth through the ERK pathway [13, 28]. This
effect has been demonstrated in diabetic neuropathy [15],
chemotherapy-induced peripheral neuropathy [16] and
antiretroviral toxic neuropathy [14]. ALCAR is very well
tolerated. Large trials have shown minimal side effects. Its
practicality is further enhanced by the fact that the drug is
active in oral preparation.
Strengths
Vigorous measures have been built into the study design.
To prevent potential bias, we utilize a double-blinded,
placebo-controlled design. To further reinforce this, data
entry and review will be handled by a monitoring commit-
tee that will be working at arm’s length from the investiga-
tors who are directly interacting with the study subjects.
Surgery will be performed by two experienced surgeons
using a standardized technique for carpal tunnel release.
To measure the effects of the therapeutic agent on nerve
regeneration, we will be using MUNE as the primary out-
come measure. This provides a physiological measure that
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can be directly compared with the data from animal stud-
ies. In addition, the protocol will also incorporate tests to
provide comprehensive information on the full range of
sensory nerve fibers.
Limitations
A potential limitation of our study is generalizability of
the results. Since we will be deliberately focusing on only
CTS patients with severe motor axonal loss, the results
may not be applicable to those with mild and moderate
disease. However, since severe carpal tunnel patients
have the lowest potential for recovery even with surgery,
it would be important to target this population. A
second limitation of the study is that it is likely under-
powered. However, since no prior studies on the effect
size and variability of ALCAR in compressive neur-
opathy are available, data from this pilot study will be
very useful in designing a full-scale study. The multiple
comparisons would also reduce the statistical power of
the study. Since this is meant to serve as an exploratory
study, these considerations are not of primary concern.
Here we present a phase II randomized control trial
design to determine the role of ALCAR in peripheral
nerve regeneration in CTS. This is the first human study
that looks at the efficacy of ALCAR in patients with
compressive neuropathy. If effective, ALCAR will repre-
sent an important adjuvant therapy for patients with
CTS. By improving motor and sensory recovery, patients





ALCAR: acetyl-L-carnitine; ANOVA: analysis of variance; CTS: carpal tunnel
syndrome; EMG: electromyography; JO: Jaret Olson; KMC: K. Ming Chan;
MC: Matthew Curran; MM: Michael Morhart; NOL: No Objection Letter;
MUNE: motor unit number estimation; QST: quantitative sensory testing;
SC: Schwann cell; SD: standard deviation.
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